Skip to main content

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting · Phase 3 · NCT05288166

Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

At a glance

Research payments reported, 2025
$440,328
U.S. investigators named
30
Sites paid
26
Planned or actual enrollment
925

About the trial

Sponsor
Eli Lilly and Company
Tested
Abemaciclib (drug), Abiraterone (drug), Prednisone or Prednisolone (drug), Placebo for Abemaciclib (drug)
Dates
Started 2022-04-14; completion 2027-10
Results posted
Yes

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

From ClinicalTrials.gov, last updated 2026-07-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $440,328 in research payments for this study in 2025 (39 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.